Notably, previous studies have demonstrated that the ECM plays a vital role in cancer progression, and focal adhesion kinase (FAK) is often associated with poor clinical outcome, highlighting FAK as a potential determinant of tumour progression and metastasis [35]. Here, PTK2 is linked to cancer.